Hecht et al. reported the results of a randomized, phase II trial comparing Pmab plus FOLFIRI with Bev plus FOLFIRI in patients with KRAS wild-type colorectal cancer after the failure of a BEV plus oxaliplatin-based chemotherapy regimen [67]. This evidence concerns the gene KRAS and colorectal cancer.